Valneva (VALN) has released an update.
Valneva and Pfizer announce promising results from the Phase 2 study of their Lyme disease vaccine candidate, VLA15, showing strong immune responses and a favorable safety profile after a second booster dose in various age groups. This vaccine, which targets six key serotypes of the Lyme-causing bacteria, could be a significant advancement as no human vaccines for Lyme disease are currently approved. The companies are advancing the candidate through ongoing Phase 3 trials with the hope of submitting for regulatory approval in 2026.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
